Unraveling the impact of SARS-CoV-2 mutations on immunity: insights from innate immune recognition to antibody and T cell responses

Front Immunol. 2024 Dec 10:15:1412873. doi: 10.3389/fimmu.2024.1412873. eCollection 2024.

Abstract

Throughout the COVID-19 pandemic, the emergence of new viral variants has challenged public health efforts, often evading antibody responses generated by infections and vaccinations. This immune escape has led to waves of breakthrough infections, raising questions about the efficacy and durability of immune protection. Here we focus on the impact of SARS-CoV-2 Delta and Omicron spike mutations on ACE-2 receptor binding, protein stability, and immune response evasion. Delta and Omicron variants had 3-5 times higher binding affinities to ACE-2 than the ancestral strain (KDwt = 23.4 nM, KDDelta = 8.08 nM, KDBA.1 = 4.77 nM, KDBA.2 = 4.47 nM). The pattern recognition molecule mannose-binding lectin (MBL) has been shown to recognize the spike protein. Here we found that MBL binding remained largely unchanged across the variants, even after introducing mutations at single glycan sites. Although MBL binding decreased post-vaccination, it increased by 2.6-fold upon IgG depletion, suggesting a compensatory or redundant role in immune recognition. Notably, we identified two glycan sites (N717 and N801) as potentially essential for the structural integrity of the spike protein. We also evaluated the antibody and T cell responses. Neutralization by serum immunoglobulins was predominantly mediated by IgG rather than IgA and was markedly impaired against the Delta (5.8-fold decrease) and Omicron variants BA.1 (17.4-fold) and BA.2 (14.2-fold). T cell responses, initially conserved, waned rapidly within 3 months post-Omicron infection. Our data suggests that immune imprinting may have hindered antibody and T cell responses toward the variants. Overall, despite decreased antibody neutralization, MBL recognition and T cell responses were generally unaffected by the variants. These findings extend our understanding of the complex interplay between viral adaptation and immune response, underscoring the importance of considering MBL interactions, immune imprinting, and viral evolution dynamics in developing new vaccine and treatment strategies.

Keywords: MBL; SARS-CoV-2; delta; immune imprinting; mannose-binding lectin; omicron; vaccine; variants of concern.

MeSH terms

  • Angiotensin-Converting Enzyme 2 / genetics
  • Angiotensin-Converting Enzyme 2 / immunology
  • Angiotensin-Converting Enzyme 2 / metabolism
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral* / immunology
  • COVID-19* / immunology
  • COVID-19* / virology
  • Humans
  • Immune Evasion / genetics
  • Immunity, Innate*
  • Immunoglobulin G / immunology
  • Mannose-Binding Lectin* / genetics
  • Mannose-Binding Lectin* / immunology
  • Mutation*
  • Protein Binding
  • SARS-CoV-2* / immunology
  • Spike Glycoprotein, Coronavirus* / genetics
  • Spike Glycoprotein, Coronavirus* / immunology
  • T-Lymphocytes* / immunology

Substances

  • Spike Glycoprotein, Coronavirus
  • Antibodies, Viral
  • spike protein, SARS-CoV-2
  • Mannose-Binding Lectin
  • Angiotensin-Converting Enzyme 2
  • Antibodies, Neutralizing
  • ACE2 protein, human
  • Immunoglobulin G

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Carlsberg Foundation (CF20-0045) Novo Nordisk Foundation (NFF205A0063505 and NNF20SA0064201) Sven Andersen Research Foundation (SARF2021) EU Horizon Europe (101057129 — REACT) This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to AG.